Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma.
Intern Med
; 60(4): 611-615, 2021 Feb 15.
Article
em En
| MEDLINE
| ID: mdl-32999219
ABSTRACT
Drug-induced immune hemolytic anemia (DIIHA) is a rare condition with an increasing incidence associated with the frequent use of certain drugs. An 85-year-old woman with lung adenocarcinoma prescribed alectinib complained of dyspnea on exertion at our hospital. Based on her laboratory tests results on admission, we focused on the clinical course of anemia and hemolysis progression after alectinib administration. The patient's anemia and hemolysis gradually improved after discontinuation of alectinib, leading to a diagnosis of alectinib-induced IHA, presented here as the first case encountered in a patient with lung adenocarcinoma. Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Adenocarcinoma de Pulmão
/
Anemia Hemolítica
/
Neoplasias Pulmonares
Limite:
Aged80
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article